Showing results (181-190 of 245) with videos related to
Sort By:
Pageof 25
Leukemia Research|September 26, 2021
Phase 1 study of the histone deacetylase inhibitor entinostat plus clofarabine for poor-risk Philadelphia chromosome-negative (newly diagnosed older adults or adults with relapsed refractory disease) acute lymphoblastic leukemia or biphenotypic leukemiaHetty E Carraway, Yazeed Sawalha, Ivana Gojo, et al.Leukemia|November 17, 2020
Venetoclax and pegcrisantaspase for complex karyotype acute myeloid leukemiaAshkan Emadi, Bandish Kapadia, Dominique Bollino, et al.Leukemia|February 24, 2023
Outcome prediction by the 2022 European LeukemiaNet genetic-risk classification for adults with acute myeloid leukemia: an Alliance studyKrzysztof Mrózek, Jessica Kohlschmidt, James S Blachly, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 10, 2004
Outcome of induction and postremission therapy in younger adults with acute myeloid leukemia with normal karyotype: a cancer and leukemia group B studySherif S Farag, Amy S Ruppert, Krzysztof Mrózek, et al.Haematologica|June 11, 2011
Clinical outcome and gene- and microRNA-expression profiling according to the Wilms tumor 1 (WT1) single nucleotide polymorphism rs16754 in adult de novo cytogenetically normal acute myeloid leukemia: a Cancer and Leukemia Group B studyHeiko Becker, Kati Maharry, Michael D Radmacher, et al.Leukemia & Lymphoma|January 8, 2015
Phase I dose escalation study of lestaurtinib in patients with myelofibrosisElizabeth O Hexner, John Mascarenhas, Josef Prchal, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 9, 2005
Overexpression of the ETS-related gene, ERG, predicts a worse outcome in acute myeloid leukemia with normal karyotype: a Cancer and Leukemia Group B studyGuido Marcucci, Claudia D Baldus, Amy S Ruppert, et al.The Lancet. Oncology|March 13, 2016
Rigosertib versus best supportive care for patients with high-risk myelodysplastic syndromes after failure of hypomethylating drugs (ONTIME): a randomised, controlled, phase 3 trialGuillermo Garcia-Manero, Pierre Fenaux, Aref Al-Kali, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 7, 2010
IDH1 and IDH2 gene mutations identify novel molecular subsets within de novo cytogenetically normal acute myeloid leukemia: a Cancer and Leukemia Group B studyGuido Marcucci, Kati Maharry, Yue-Zhong Wu, et al.JAMA Oncology|November 21, 2024
Olverembatinib After Failure of Tyrosine Kinase Inhibitors, Including Ponatinib or Asciminib: A Phase 1b Randomized Clinical TrialElias Jabbour, Vivian G Oehler, Paul B Koller, et al.Pageof 25